ReviewInternational journal of clinical and experimental medicine2015
CYP1A1 MspI polymorphism and susceptibility to lung cancer in the Chinese population: an updated meta-analysis and review.
Review in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
- Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer.Seminars in cancer biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough many epidemiologic studies have investigated the CYP1A1 MspI gene polymorphisms and their associations with lung cancer (LC), definite conclusions cannot be drawn.
objectiveTo clarify the effects of CYP1A1 MspI polymorphisms on the risk of LC, an update meta-analysis was performed in only Chinese population.
methodsRelated studies were identified from PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biology Medicine (CBM) till October 2014. Pooled ORs and 95% CIs were used to assess the strength of the associations.
resultsA total of 22 studies including 3016 LC cases and 3932 controls were involved in this meta-analysis. Overall, significant association was found between CYP1A1 MspI polymorphism and LC risk when all studies in the Chinese population pooled into this meta-analysis (CC vs. TT: OR = 1.42, 95% CI = 1.11-1.80; CT + CC vs. TT: OR = 1.26, 95% CI = 1.06-1.50; CC vs. CT + TT: OR = 1.30, 95% CI = 1.04-1.61; C vs. T: OR = 1.21, 95% CI = 1.07-1.37). In subgroup analyses stratified by ethnicity and source of controls, significantly increased risk was found in Chinese Han people and in population-based studies.
conclusionsThis meta-analysis provides the evidence that CYP1A1 MspI polymorphism may contribute to the LC development in the Chinese population and studies with large sample size and wider spectrum of population are warranted to verify this finding.
Indexed as
Identifiers
26550103PMC4612788W2416762489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.